Stockpolly
Search
Delisting risk
VIVS · NASDAQ · Biotechnology

VivoSim Labs (VIVS)

Preclinical liver and intestinal toxicology testing with primary human tissue models.

$0.2800
Pre-market+0.00 (+0.07%)
At close$0.2798(+0.39%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY24Sep 2023Q3 FY24Dec 2023Q4 FY24Mar 2024Q1 FY25Jun 2024Q2 FY25Sep 2024Q3 FY25Dec 2024Q4 FY25Mar 2025Q1 FY26Jun 2025Q2 FY26Sep 2025Q3 FY26Dec 2025Q4 FY26Mar 2026Q1 FY27Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
443333333333
Research & development111112111111
322222222222
General & administrative322222222222
Other expenses000000000000
Operating income−4−4−3−3−3−3−3−3−3−3−3−3
00000010000−31
Interest income000000000000
Interest expense000000000000
Other non-operating income000000−100003−1
Income before tax−4−4−3−3−3−37−3−3−3−6−1
Income tax expense000000000000
Net income from continuing operations−4−4−3−3−3−37−3−3−3−6−1
Net income−4−4−3−3−3−37−3−3−3−6−1
EPS, basic−$5.50−$4.74−$3.07−$2.74−$1.70−$2.29$4.68−$1.94−$1.74−$1.84−$2.21−$0.25
EPS, diluted−$5.50−$4.74−$3.07−$2.74−$1.70−$2.29$4.68−$1.94−$1.74−$1.84−$2.21−$0.25
Weighted average shares, basic111112111135
Weighted average shares, diluted111112111135
EBITDA−4−4−3−3−2−37−3−2−3−6−1
Depreciation & amortization000000000000
EBIT−4−4−3−3−3−37−3−3−3−6−1